



17 February 2016, Melbourne, Australia: Opthea Limited (ASX:OPT) has featured in CommSec's *Executive Series*. The Series interviews leading CEOs from ASX-listed companies and is hosted by Tom Piotrowski, a high profile market analyst.

Released this week, the interview is distributed internally in CommSec's Weekly wrap-up to over 50,000 clients as well as uploaded to the CommSec website and YouTube channel CommSecTV.

To view the interview, please click on the link:

<https://youtu.be/smRPltEx88I>

Company & Media Enquiries:

Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 3 9826 0399
Megan.baldwin@opthea.com

Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com

About Opthea Limited

Opthea (ASX:OPT; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD).